Drugs / ALVAC(2)-NY-ESO-1(M)/TRICOM
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00803569 | Nov 2008 → Jan 2011 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALVAC(2)-NY-ESO-1(M)/TRICOM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00803569 ↗ |
| Known as | VCP2292 | “Phase I Study of ALVAC(2)-NY-ESO-1(M)/TRICOM (VCP2292) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma” NCT00803569 ↗ |
| Modality | Vaccine | “ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine” NCT00803569 ↗ |
| Route | Subcutaneous | “Patients received subcutaneous (SC) injections with 0.5 mL of ALVAC(2)-NY-ESO-1(M)/TRICOM on Day 1” NCT00803569 ↗ |